275 results on '"Alvarez-Larran A"'
Search Results
2. P667: RISK OF PROGRESSION IN CHRONIC PHASE-CHRONIC MYELOID LEUKEMIA PATIENTS ELIGIBLE FOR TYROSINE KINASE INHIBITOR DISCONTINUATION: FINAL ANALYSIS OF THE TFR-PRO STUDY
3. P1054: CLINICAL CHARACTERISTICS AND OUTCOMES IN 175 PATIENTS WITH MYELOFIBROSIS ACCORDING TO GENOMIC CLASSIFICATION USING NEXT-GENERATION SEQUENCING
4. CNL and aCML should be considered as a single entity based on molecular profiles and outcomes
5. Breakthrough infections in MPN-COVID vaccinated patients
6. Increased risk of thrombosis in JAK2 V617F-positive patients with primary myelofibrosis and interaction of the mutation with the IPSS score
7. Appropriate management of polycythaemia vera with cytoreductive drug therapy: European LeukemiaNet 2021 recommendations
8. Managing hematological cancer patients during the COVID-19 pandemic: an ESMO-EHA Interdisciplinary Expert Consensus
9. Second versus first wave of COVID-19 in patients with MPN
10. Breakthrough infections in MPN-COVID vaccinated patients
11. Increased risk of thrombosis in JAK2 V617F-positive patients with primary myelofibrosis and interaction of the mutation with the IPSS score
12. Direct oral anticoagulants for myeloproliferative neoplasms: results from an international study on 442 patients
13. DNMT3A/TET2/ASXL1 mutations are an age-independent thrombotic risk factor in polycythemia vera patients: an observational study
14. Unmet clinical needs in the management of CALR-mutated essential thrombocythaemia: a consensus-based proposal from the European LeukemiaNet
15. Correction to: Low‑risk polycythemia vera treated with phlebotomies: clinical characteristics, hematologic control and complications in 453 patients from the Spanish Registry of Polycythemia Vera
16. Long-term follow-up of recovered MPN patients with COVID-19
17. Among classic myeloproliferative neoplasms, essential thrombocythemia is associated with the greatest risk of venous thromboembolism during COVID-19
18. Predicting Survival after Allogeneic Hematopoietic Cell Transplantation in Myelofibrosis: Performance of the Myelofibrosis Transplant Scoring System (MTSS) and Development of a New Prognostic Model
19. High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib
20. Ropeginterferon phase 2 randomized study in low-risk polycythemia vera: 5-year drug survival and efficacy outcomes
21. PB0954 Endothelial Dysfunction in Myeloproliferative Neoplasms Debuting with Splanchnic Vein Thrombosis
22. P1009: PREDICTORS OF HOSPITALIZATION AND SEVERE OUTCOMES IN PATIENTS WITH MPN AND COVID-19
23. Risk of progression in chronic phase‐chronic myeloid leukemia patients eligible for tyrosine kinase inhibitor discontinuation: Final analysis of the TFR‐PRO study
24. P1054: CLINICAL CHARACTERISTICS AND OUTCOMES IN 175 PATIENTS WITH MYELOFIBROSIS ACCORDING TO GENOMIC CLASSIFICATION USING NEXT-GENERATION SEQUENCING
25. P667: RISK OF PROGRESSION IN CHRONIC PHASE-CHRONIC MYELOID LEUKEMIA PATIENTS ELIGIBLE FOR TYROSINE KINASE INHIBITOR DISCONTINUATION: FINAL ANALYSIS OF THE TFR-PRO STUDY
26. Among classic myeloproliferative neoplasms, essential thrombocythemia is associated with the greatest risk of venous thromboembolism during COVID-19
27. Second cancer in Philadelphia negative myeloproliferative neoplasms (MPN-K). A nested case-control study
28. Toxicity of Asciminib in Real Clinical Practice; Analysis of Side Effects and Cross-Intolerance with Tyrosine Kinase Inhibitors
29. Protection Against Breakthrough Delta/Omicron Variants in Vaccinated Patients with Myeloproliferative Neoplasms (MPN)
30. Risk of Progression in Chronic Phase-Chronic Myeloid Leukemia (CML) Patients Eligible for Tyrosine Kinase Inhibitor Discontinuation: The Tfr-PRO Study
31. Coexisting Myeloproliferative and Lymphoproliferative Neoplasms: A European Multicenter Retrospective Study
32. Characterization of CD34+ hematopoietic progenitor cells in JAK2V617F and CALR-mutated myeloproliferative neoplasms
33. BCL2 gene polymorphisms and splicing variants in chronic myeloid leukemia
34. Molecular characterization of atypical chronic myeloid leukemia and chronic neutrophilic leukemia
35. Discrimination between tumour epithelium and stroma via perception-based features
36. Essential thrombocythemia: Baseline characteristics and risk factors for survival and thrombosis in a series of 214 patients
37. Dual Inhibition of NF-Kb and JAK/STAT Pathways Reverts Myelofibrosis-like Phenotype in an In Vivo Murine Model
38. Coexisting Myeloproliferative and Lymphoproliferative Neoplasms: A European Multicenter Retrospective Study
39. Risk of Progression in Chronic Phase-Chronic Myeloid Leukemia (CML) Patients Eligible for Tyrosine Kinase Inhibitor Discontinuation: The Tfr-PRO Study
40. Protection Against Breakthrough Delta/Omicron Variants in Vaccinated Patients with Myeloproliferative Neoplasms (MPN)
41. Toxicity of Asciminib in Real Clinical Practice; Analysis of Side Effects and Cross-Intolerance with Tyrosine Kinase Inhibitors
42. Machine Learning Improves Risk Stratification in Myelofibrosis: An Analysis of the Spanish Registry of Myelofibrosis
43. Determinants of early triage for hospitalization in myeloproliferative neoplasm (MPN) patients with COVID-19
44. Determinants of early triage for hospitalization in myeloproliferative neoplasm ( MPN) patients with COVID ‐19
45. MPN-135 Safety and Efficacy of Pelabresib in Combination With Ruxolitinib for JAK Inhibitor-Naïve Patients With Myelofibrosis: Latest Data From the Phase 3 MANIFEST-2 Study
46. Safety and Efficacy of Pelabresib in Combination With Ruxolitinib for JAK Inhibitor-Naïve Patients With Myelofibrosis: Latest Data From the Phase 3 MANIFEST-2 Study
47. Dual Inhibition of NF-Kb and JAK/STAT Pathways Reverts Myelofibrosis-like Phenotype in an In Vivo Murine Model
48. P1009: PREDICTORS OF HOSPITALIZATION AND SEVERE OUTCOMES IN PATIENTS WITH MPN AND COVID-19
49. Genetic predisposition to molecular response in patients with myeloproliferative neoplasms treated with hydroxycarbamide
50. Determinants of early triage for hospitalization in MPN patients with COVID-19
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.